Aflibercept Injection [Eylea]

Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1

Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan

Diabetic Macular Edema Asian Response (DEAR) Study: Biomarkers for Response to Aflibercept in Asian Patients With Center Involving DME

Treatment of CNV With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3

Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept Injection

Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion

Effect Aflibercept on Ocular Perfusion

Intravitreal Aflibercept Injection or Early Vitrectomy for Diabetic Vitreous Hemorrhage

Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity

Mean Visual Acuity Changes Following Five Injections of Aflibercept

Assessment of Biomarker Profile in Diabetic Macular Edema With Intravitreal Aflibercept Injection

Navigated Laser In Branch Retinal Vein Occlusion Study

One Year Results of Switching to Aflibercept for Persistent Diabetic Macular Edema Resistant to Bevacizumab

Maximum Treatment Interval With Aflibercept T&E